Tennessee Code Annotated

Tenn. Code Ann. § 53-1-110 (2026)

Sale of new drugs

✓ current as of May 2026
Find cases: SyfertCases citing this section JustiaTenn. Code CornellLII Search CasesGoogle Scholar

Acts 1941, ch. 120, § 17; C. Supp. 1950, § 6580.17; Acts 1963, ch. 226, § 2; T.C.A. (orig. ed.), § 52-117; Acts 1986, ch. 485, § 1.


Notes of Decisions
Cited in 2 cases (2 in the last 5 years), 2025–2025 · leading case: Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025).
Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Zyla Life Sciences v. Wells Pharma. (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
— Tenn. Code Ann. § 53-1-110(a) — 2 cases
Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Zyla Life Sciences v. Wells Pharma. (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.